2,5-dimethyl Celecoxib NEW
Price | $54 | $128 | $189 |
Package | 1mg | 5mg | 10mg |
Min. Order: | |
Supply Ability: | 10g |
Update Time: | 2024-11-19 |
Product Details
Product Name: 2,5-dimethyl Celecoxib | CAS No.: 457639-26-8 |
Purity: 99.94% | Supply Ability: 10g |
Release date: 2024/11/19 |
Product Introduction
Bioactivity
Name | 2,5-dimethyl Celecoxib |
Description | 2,5-dimethyl Celecoxib is a celecoxib derivative and a targeted inhibitor of microsomal prostaglandin E synthase-1 (mPGES-1), a key enzyme in the PGE2 synthesis pathway of inflammatory mediators. |
In vitro | 2,5-dimethyl Celecoxib(1–100?μM) decreased the viability of GBM cell lines in a dose-dependent manner. 2,5-dimethyl Celecoxib downregulated β-catenin target genes expression in A-172, T98G and U-138 MG cell lines. Apoptosis was induced, and cell cycle distribution was altered after the treatment with 2,5-dimethyl Celecoxib in T98G cell line.2,5-dimethyl Celecoxib downregulated β-catenin target genes expression in patient-derived primary GBM cell lines P1 and P6[1]. |
In vivo | 2,5-dimethyl Celecoxib prevented cardiac remodeling and markedly reduced urinary albumin excretion without altering blood pressure in mice. 2,5-dimethyl Celecoxib prevented podocyte injury, glomerulosclerosis, and interstitial fibrosis in the kidney of mice loaded with angiotensin II and high-salt load. 2,5-dimethyl Celecoxib reduced the phosphorylation level of Akt and activated glycogen synthase kinase-3, which led to the suppression of the Wnt/β-catenin signal in the heart and kidney. 2,5-dimethyl Celecoxib also reduced the expression level of snail, a key transcription factor for the epithelial–mesenchymal transition and of which gene is a target of the Wnt/β-catenin signal[2]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | Ethanol : 3 mg/mL DMSO : 60 mg/mL (151.75 mM) DMF : 5 mg/mL DMSO:PBS (pH 7.2) (1:3) : 0.25 mg/mL |
Keywords | 2,5-dimethyl Celecoxib | 2,5dimethyl Celecoxib | 2,5 dimethyl Celecoxib |
Inhibitors Related | Stavudine | Sodium 4-phenylbutyrate | Tributyrin |
Related Compound Libraries | Anti-Colorectal Cancer Compound Library | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Ovarian Cancer Compound Library | Neuroprotective Compound Library | Inhibitor Library | Bioactive Compounds Library Max | GPCR Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY